Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zabalafin Hydrogel for pediatric molluscum contagiosum
ACTRN12626000303347Phase 2Active, not recruiting
- Sponsor
- Alphyn Biologics
- Start
- Jan 2026
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, randomised trial in molluscum contagiosum (MC) comparing Zabalafin Hydrogel 9.5% with Vehicle Gel (2 arms). Started Jan 2026; status: active, not recruiting.
02
Drugs
zabalafin
03
Conditions
molluscum contagiosum (MC)
Beyond the preview
Go deeper on ACTRN12626000303347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000303347.